N501Y

Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane

Retrieved on: 
Wednesday, December 29, 2021
N501Y, Gene, COVID-19, Infection, Laboratory, RNA-dependent RNA polymerase, CEO, HY, Animal, Pharmaceutical industry, Omicron

A total of 1.7 million Allplex SARS-CoV-2 Master Assays and associated consumables will be sent on December 29.

Key Points: 
  • A total of 1.7 million Allplex SARS-CoV-2 Master Assays and associated consumables will be sent on December 29.
  • Seegene's Allplex SARS-CoV-2 Master Assay can determine whether a person is infected with the SARS-CoV-2 virus and if he/she has contracted the Omicron variant.
  • It targets four genes (E, RdRP, N, and S), along with five mutations: HV69/70 deletion, Y144 deletion, E484K, N501Y, P681H.
  • "Demand for tests has soared dramatically following the emergence and rapid spread of the Omicron variant," said Dr. Jong-YoonChun, Seegene Founder and CEO.

Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane

Retrieved on: 
Wednesday, December 29, 2021
N501Y, Gene, COVID-19, Infection, Laboratory, RNA-dependent RNA polymerase, CEO, HY, Animal, Pharmaceutical industry, Omicron

A total of 1.7 million Allplex SARS-CoV-2 Master Assays and associated consumables will be sent on December 29.

Key Points: 
  • A total of 1.7 million Allplex SARS-CoV-2 Master Assays and associated consumables will be sent on December 29.
  • Seegene's Allplex SARS-CoV-2 Master Assay can determine whether a person is infected with the SARS-CoV-2 virus and if he/she has contracted the Omicron variant.
  • It targets four genes (E, RdRP, N, and S), along with five mutations: HV69/70 deletion, Y144 deletion, E484K, N501Y, P681H.
  • "Demand for tests has soared dramatically following the emergence and rapid spread of the Omicron variant," said Dr. Jong-YoonChun, Seegene Founder and CEO.

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on: 
Thursday, December 9, 2021
PCR, RT, COVID-19, Technology, Stealth, World Health Organization, RNA-dependent RNA polymerase, Multimedia, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.

Key Points: 
  • The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
  • Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
  • Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.
  • Today, Seegene is able to rapidly develop new tests ahead of emerging variants using the company's big data auto-surveillance in silico system.

Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube

Retrieved on: 
Thursday, December 9, 2021
PCR, RT, COVID-19, Technology, Stealth, World Health Organization, Alpha, RNA-dependent RNA polymerase, World, N501Y, Alpha-beta model, KQ, Severe acute respiratory syndrome coronavirus 2, WHO, Medical device, Vaccine

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants. Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.

Key Points: 
  • The new assay identifies positive COVID-19 cases and distinguishes between Alpha, Beta, Gamma, Delta, Omicron and its Stealth version.
  • The Novaplex SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants.
  • Seegene believes the new PCR test will be effective in helping governments and health authorities to fight current variants.
  • Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, Seegene implemented its AI-based in-silico system to conclude this development within a week.

Bruker Expects its FluoroType® SARS-CoV-2 varID Q PCR Assay to Reliably Detect and Tentatively Differentiate Omicron (B.1.1.529) Variant

Retrieved on: 
Thursday, December 2, 2021
Medical Devices, Health, Infectious Diseases, Hospitals, Pharmaceutical, Biotechnology, N501Y, PCR, Viral load, WHO, Alpha, Severe acute respiratory syndrome coronavirus 2, Bruker, B.1.1.7, Nasdaq, CP, Corporation, Multimedia, XT, Typesetting, Bruker Molecular Diagnostics, Bruker Corporation, BRUKER MOLECULAR DIAGNOSTICS, BRUKER CORPORATION

View the full release here: https://www.businesswire.com/news/home/20211202005759/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211202005759/en/
    FluoroType SARS-CoV-2 varID Q PCR Kit (Photo: Business Wire)
    FluoroType SARS-CoV-2 varID Q is a multiplexed CE-IVD marked PCR assay for the detection and quantification of all major SARS-CoV-2 variants, based on Brukers proprietary LiquidArray technology.
  • In addition, the assay simultaneously detects the S-gene mutations Del69-70 and N501Y, which are expected to be clear indications that the variant is Omicron (B.1.1.529).
  • Using the FluoroType SARS-CoV-2 varID Q assay allows the user to run a screening tool for detecting SARS-CoV-2, viral load and an early indication of the Omicron variant.
  • Moreover, Bruker is pleased to confirm that their full range of other FluoroType SARS-CoV-2 assays are also expected to reliably detect the Omicron variant (B.1.1.529).

Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
PCR, WHO, N501Y, World, World Health Organization, CEO, Quarantine, KQ, VOC, COVID-19, RNA-dependent RNA polymerase, Vaccine

This provides accurate results on whether a person is positive for COVID-19 and if they have the Omicron variant within 4 hours.

Key Points: 
  • This provides accurate results on whether a person is positive for COVID-19 and if they have the Omicron variant within 4 hours.
  • Since the latest variant Omicron contains HV69/70 deletion, N501Y, and P681H mutations, this CE-IVD marked test can detect Omicron.
  • For more rapid detection, Seegene's Allplex SARS-CoV-2 Master Assay can detect the variant in the very first stage of screening.
  • "In order to contain the further spread of Omicron, it is extremely important to preemptively detect the Omicron variant at the primary screening stage.

Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
N501Y, World Health Organization, CEO, KQ, PCR, WHO, World, COVID-19, View, Quarantine, Multimedia, VOC, RNA-dependent RNA polymerase, Vaccine

This provides accurate results on whether a person is positive for COVID-19 and if they have the Omicron variant within 4 hours.

Key Points: 
  • This provides accurate results on whether a person is positive for COVID-19 and if they have the Omicron variant within 4 hours.
  • Since the latest variant Omicron contains HV69/70 deletion, N501Y, and P681H mutations, this CE-IVD marked test can detect Omicron.
  • For more rapid detection, Seegene's Allplex SARS-CoV-2 Master Assay can detect the variant in the very first stage of screening.
  • "In order to contain the further spread of Omicron, it is extremely important to preemptively detect the Omicron variant at the primary screening stage.

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Retrieved on: 
Friday, November 26, 2021
Research, Medical Supplies, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Private Securities Litigation Reform Act, Degenerative disease, N501Y, Government, Safety, NIH, Annual report, Company, Severe acute respiratory syndrome coronavirus 2, SEC, Therapy, Vaccine, COVID-19, National, U.S. Securities and Exchange Commission, Omicron, View, Risk, Biotechnology, MRNA, RNA, Science, RNA transfection, Infection, Intention, Fertilizer

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.
  • This strategy includes three levels of response should the currently authorized 50 g booster dose of mRNA-1273 prove insufficient to boost waning immunity against the Omicron variant.
  • The first candidate (mRNA-1273.211) includes several mutations present in the Omicron variant that were also present in the Beta variant of concern1.
  • The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant, said Stphane Bancel, Chief Executive Officer of Moderna.

NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research

Retrieved on: 
Friday, November 26, 2021
Coronavirus, Company, National Security Advisor (United States), BARDA, JD, Immunity, GLOBE, Letter, Biotechnology, Development, Israel Institute for Biological Research, Human services, Food, N501Y, CEO, United States Army, COVID-19, Biomedical Advanced Research and Development Authority, National, Review, Biology, Health, MPH, Goal, J&J, Fast Track, FDA, Patient, Dark Enlightenment, US Foods, Randomized controlled trial, Breakthrough therapy, Acquisition, Novartis, Severe acute respiratory syndrome coronavirus 2, ASPE, IIBR-100, Manuscript, Lilly, Data monitoring committee, Antibody, NASDAQ, Vaccine, Pharmaceutical industry

A second group of blood samples (sera) were drawn from unvaccinated patients who contracted and recovered from Covid-19.

Key Points: 
  • A second group of blood samples (sera) were drawn from unvaccinated patients who contracted and recovered from Covid-19.
  • Those patients had antibodies against the wild-type Coronavirus but with a 3.8 fold reduction in immune response (neutralizing titers) to the Delta variant.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • The Company is developing the BriLife Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense.

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Retrieved on: 
Thursday, September 23, 2021
Technology, Research, Infectious Diseases, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Science, Blood, NGS, Animal, Weight loss, La Jolla Institute for Immunology, Risk, RNA, Security (finance), Therapy, Top of the Form (quiz show), USAMRIID, Private Securities Litigation Reform Act, DNA, Doctor of Philosophy, Immunoglobulin G, U.S. Securities and Exchange Commission, Patient, Engineering, Infection, Martek Biosciences Corporation, COVID-19, Twist Bioscience, Biology, CEO, N501Y, Human, Genomics, Antibody, Agriculture, Immunology, Technology, Severe acute respiratory syndrome coronavirus 2, VHH, Synthetic biology, RBD, Silicon, Drug discovery, ACE2, United States Army Medical Research Institute of Infectious Diseases, Peplomer, Čović, Time, Urinary tract infection, Mutation, SEC, Vaccine, Pharmaceutical industry, Twist Biopharma Antibodies, The Coronavirus Immunotherapy Consortium (CoVIC), Twist Bioscience Corporation, TWIST BIOPHARMA ANTIBODIES, THE CORONAVIRUS IMMUNOTHERAPY CONSORTIUM (COVIC), TWIST BIOSCIENCE CORPORATION

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.